ALLiance for SEcondary PREvention After an Episode of Acute Coronary Syndrome (ALLEPRE) (ALLEPRE)

March 23, 2025 updated by: Diego Ardissino, Azienda Ospedaliero-Universitaria di Parma

ALLiance for SEcondary PREvention After an Episode of Acute Coronary Syndrome. the ALLEPRE Trial: a Fully Nurse-led Intensive Intervention Programme

The purpose of the ALLEPRE trial is to compare the benefit offered by a structured, intensive and fully nurse-led intensive secondary prevention intervention programme with that offered by standard of care in a high-risk population of patients admitted to hospital because of an ACS.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

ALLEPRE enrols a population of residents in Emilia Romagna with a diagnosis of ACS (unstable angina, non-ST segment elevation myocardial infarction, ST segment elevation myocardial infarction) who were admitted to the specialist cardiological departments of the participating centres up to 20 days after the index event.

All eligible patients are randomised 1:1 to the nurse-led intensive secondary prevention programme (ISPP: intervention/experimental arm) or usual treatment (UT: control arm).

Randomisation is centralised by means of IVRS under the responsibility of the Study Coordinator and the Principal Investigator at each hospital centre, and the patients are the allocated to groups by e-mail. Due to the nature of the study, neither participants nor research personnel can be blinded to the group assignments. The randomisation data are kept at the coordinating centre.

OPERATIVE PHASE After randomisation, all of the patients in both arms undergo a baseline examination and are required to return to their reference centre for follow-up visits after 12, 24 and 60 months for outcome assesment. Outcomes will also be recorded after 36 and 48 months on the basis of telephone enquiries.

ISPP: intervention arm. This consists of a series of programmed sessions involving the centrally trained nurses and the patients randomised to the ISPP. There will be a total of nine sessions: before discharge, and one, three, six, 12, 18, 24, 36 and 48 months after discharge. During the sessions, each of which will last for about one hour, the trained nurse will record the main clinical parameters (i.e. risk factors, lifestyle habits, adherence to therapy, and any discrepancies between patient reports and the recommended goals) using an ad hoc clinical file (SIM: scheda infermieristica multidimensionale or multidimensional nursing form), and then activate the interventions laid down by the pre-specified rules inside the SIM in order to correct the discrepancies. The activation of the pre-established multidisciplinary network (anti-smoking, anti-diabetes and anti-hypertension centres, and psychological support) is completely under the nurses' control.

Caregivers are encouraged to support the patients in achieving behavioural changes over time.

Adherence to the proven secondary prevention treatments is monitored using the Morisky scale in order to ensure that each of the following classes of cardioprotective medications are prescribed according to the guidelines at the doses used in clinical trials: antiplatelet therapy, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, and statins. The reasons for non-adherence also investigated in order to ensure more targeted interventions. The risk factor and lifestyle behaviour goals are to stop smoking, eat a healthy Mediterranean diet, undertake physical activity for at least 30 minutes/day on five days/week, and maintain a body mass index (BMI) of <25 kg/m2, systolic blood pressure of <140, LDL cholesterol levels of <70 mg/dL (1.81 mmol/L). A further goal for all diabetic subjects is good glycemic control.

The nurses also assess the subjects' psychological characteristics by means of a questionnaire that measures anxiety, depression, anger and hostility, type A and type D personality, perceived social support and perceived self-efficacy, and use an ad hoc questionnaire for referral to a psychologist if necessary.

To ensure the same nurse intervention in all partecipating centers the study started with a preliminary TRAINING PHASE involving professional nurses proposed by the participating centres (6-10 per centre, 50% from a hospital setting, 50% from a community setting). The training programme was coordinated by the Training and Continuous Education Centre of Parma University Hospital, and delivered by a multidisciplinary team of medical/nursing/psychological experts with the aid of ad hoc paper-based teaching materials. It consisted of three 8-hour sessions held on consecutive days during which the nurses were trained in secondary CVD prevention and how to take multi-dimensional and structured responsibility for ACS patients using appropriate communication strategies aimed at reducing risk factors, modifying lifestyles and improving adherence to prescribed pharmacological therapy. The programme was repeated four times in order to allow the creation of small groups (20 participants) and better interactions.

UT: control arm. The patients randomised to the control group will follow the standard for secondary prevention of the hospital to which they were admitted.

DATA MANAGEMENT All of the data are peripherally recorded in electronic case report forms and stored for further analysis. An external monitoring provides for all partecipating centrers the clinical data verification, the accuracy and the completeness of electronic case report forms.

Sample size and statistical aspects On the basis of the results of the GRACE UK-Belgian Study, it is conservatively expected that the cumulative rate of clinical endpoints in the standard care arm (cardiovascular mortality, non-fatal reinfarction, non-fatal stroke) during the five years' follow-up will be 28%. Using the formula of Lakatos and Lan (Statistics in Medicine, 1992), in order to detect a 25% risk reduction in the experimental group, with 90% power and a two-sided significance level of 0.25, at least 1030 patients are required in each group.

However, a two-year interim analysis of the major clinical endpoint will show the real divergence of the curves and provide further information for estimating the required duration of the study more precisely. The estimated sample size is also valid for the analysis of the first primary endpoint.

The plan of the primary and secondary analyses includes a Kaplan-Meier analysis of the time to an event, the HR, and log-rank comparisons based on the ITT and PP populations.

The baseline characteristics of the intervention and control group will be compared using the chi-squared test for categorical factors and Student's t test for independent samples for continuous factors. The data will be expressed as mean values ± standard deviations. All of the statistical analyses will be made using the SPSS programme.

A secondary heterogeneity analysis of the primary clinical outcomes will be made by stratifying the patients by age, sex, center, literacy level, diabetes, hypertension, smoking habits, family history, type of myocardial infarction (STEMI vs NSTEMI), and hospital characteristics. Analysis of repeated measures will be used to evaluate the changes in the primary surrogate end point over time.

Study Type

Interventional

Enrollment (Actual)

2060

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Italy
      • Parma, Italy, 43126
        • Azienda Ospedaliero-Universitaria di Parma
      • Piacenza, Italy, 29121
        • Ospedale Guglielmo da Saliceto
    • Modena
      • Baggiovara, Modena, Italy, 41126
        • Ospedale di Baggiovara
      • Carpi, Modena, Italy, 41012
        • Ospedale Ramazzini di Carpi
    • Parma
      • Fidenza, Parma, Italy, 43036
        • Ospedale di Vaio
    • Reggio Emilia
      • Castelnovo ne' Monti, Reggio Emilia, Italy
        • Ospedale Sant'Anna
      • Guastalla, Reggio Emilia, Italy, 42020
        • Ospedale Civile di Guastalla

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Eligible patients aged >18 years with an ACS (unstable angina, non- ST-segment elevation myocardial infarction [MI], or ST-segment elevation MI [International Classification of Diseases, Ninth Revision, Clinical Modification codes 41071, 41001, 41011, 41021, 41031, 41041, 41051,41061, 41081, and 41091]) who are admitted to the Cardiological Divisions of the 6 participating centers in Emilia-Romagna (Italy) are considered for enrolment for up to 20 days after the index event and before being discharged.

Exclusion Criteria:

Once it has been verified that the patients are capable of participating in a prospective study, the only exclusion criterion is a life expectancy of b12 months because of a severe noncardiac disease

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intensive Secondary Prevention Programme
The Nurse-led Intensive Secondary Prevention Programme consists of programmed 9 sessions involving the trained nurses and the patients randomised to the experimental programme: before discharge, and one, three, six, 12, 18, 24, 36 and 48 months follow up. During the sessions the nurse will record the main clinical parameters (risk factors, lifestyle habits, adherence to therapy, psychological characteristics), any discrepancies between patient reports and the recommended goals and then activate the interventions in order to correct the discrepancies. The activation of the pre-established multidisciplinary network (anti-smoking, anti-diabetes and anti-hypertension centres, and psychological support) is completely under the nurses' control.
Behavioral: Nurse-led Intensive Secondary Prevention Programme
Information related to intervention description have been already included in arm/group description
Active Comparator: Usual Treatment
The patients randomised to the control group will follow the Usual Treatment for secondary prevention of the hospital to which they were admitted
Behavioral: Usual Treatment
Information related to intervention description have been already included in arm/group description

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The difference in the degree of adherence to the goals concerning risk factors, lifestyle modifications and pharmacological therapy.
Time Frame: 24 months

Adherence to the goals of classic cardiovascular risk factors:

- number of patients (nop) with systolic blood pressure <140 mmHg, divided by total nop.
24 months
The difference in the degree of adherence to the goals concerning risk factors, lifestyle modifications and pharmacological therapy.
Time Frame: 24 months

Adherence to the goals of classic cardiovascular risk factors:

- nop with LDL cholesterol <70 mg/dL, divided by total nop.
24 months
The difference in the degree of adherence to the goals concerning risk factors, lifestyle modifications and pharmacological therapy.
Time Frame: 24 months

Adherence to the goals of classic cardiovascular risk factors:

- number of non-smokers, divided by the total nop.
24 months
The difference in the degree of adherence to the goals concerning risk factors, lifestyle modifications and pharmacological therapy.
Time Frame: 24 months

Adherence to the goals of classic cardiovascular risk factors:

- nop with HbAC1 <7%, divided by total nop.
24 months
The difference in the degree of adherence to the goals concerning risk factors, lifestyle modifications and pharmacological therapy.
Time Frame: 24 months
The number of patients with the target body mass index (18-24.9) divided by the total nop.
24 months
The difference in the degree of adherence to the goals concerning risk factors, lifestyle modifications and pharmacological therapy.
Time Frame: 24 months

Adherence to life style modifications:

- Number of patients eating at least 5 servings friut/vegetable/day divided by total nop at month 24.
24 months
The difference in the degree of adherence to the goals concerning risk factors, lifestyle modifications and pharmacological therapy.
Time Frame: 24 months
The number of patients eating at least 2 fish servings/wk divided by the total
24 months
The difference in the degree of adherence to the goals concerning risk factors, lifestyle modifications and pharmacological therapy.
Time Frame: 24 months

Adherence to life style modifications:

The number of patients spending at least 30 min/d, 5 times/wk on recreational exercise divided by the total number of patients.
24 months
The difference in the degree of adherence to the goals concerning risk factors, lifestyle modifications and pharmacological therapy.
Time Frame: 24 months

Adherence to medications:

The number of patients with a high degree of adherence to medications (Morisky Medication Adherence Scale score 3-4) divided by the total nop.
24 months
Major adverse events
Time Frame: 5 years
Composite of cardiovascular mortality, non-fatal reinfarction, non-fatal stroke
5 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical endpoints
Time Frame: 5 years
a composite of cardiovascular mortality, nonfatal reinfarction, and nonfatal troke and myocardial ischemia-driven revascularization.
5 years
Clinical endpoints
Time Frame: 5 years
non-fatal reinfarction
5 years
Clinical endpoints
Time Frame: 5 years
non-fatal stroke
5 years
Clinical endpoints
Time Frame: 5 years
cardiovascular mortality
5 years
Clinical endpoints
Time Frame: 5 years
All-cause mortality
5 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Azienda Ospedaliero-Universitaria di Parma

Investigators

  • Principal Investigator: Diego Ardissino, MD, Azienda Ospedaliero-Universitaria di Parma

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

October 1, 2012

Primary Completion (Actual)

January 31, 2025

Study Completion (Actual)

January 31, 2025

Study Registration Dates

First Submitted

July 21, 2015

First Submitted That Met QC Criteria

August 11, 2015

First Posted (Estimated)

August 13, 2015

Study Record Updates

Last Update Posted (Estimated)

March 26, 2025

Last Update Submitted That Met QC Criteria

March 23, 2025

Last Verified

August 1, 2023

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • E35E09000880002

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acute Coronary Syndrome

Clinical Trials on Nurse-led Intensive Secondary Prevention Programme

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe